Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.3400
-0.0100 (-2.86%)
At close: Aug 17, 2026, 4:00 PM EDT
0.3401
+0.0001 (0.03%)
Pre-market: Aug 18, 2026, 4:05 AM EDT
Nexalin Technology Revenue
Nexalin Technology had revenue of $12.16K in the quarter ending June 30, 2026, a decrease of -82.77%. This brings the company's revenue in the last twelve months to $217.16K, up 24.22% year-over-year. In the year 2025, Nexalin Technology had annual revenue of $301.65K with 78.78% growth.
Revenue (ttm)
$217.16K
Revenue Growth
+24.22%
P/S Ratio
34.50
Revenue / Employee
$27,144
Employees
8
Market Cap
7.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 301.65K | 132.93K | 78.78% |
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| WORK Medical Technology Group LTD | 10.72M |
| Picard Medical | 5.47M |
| Biomerica | 4.33M |
| IceCure Medical | 3.95M |
| Intelligent Bio Solutions | 3.91M |
| Sintx Technologies | 1.33M |
| Co-Diagnostics | 721.39K |
NXL News
- 5 days ago - Nexalin Technology Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Nexalin Technology Proxy statement: Proxy filing - Filings
- 7 weeks ago - Nexalin Technology Proxy statement: Proxy filing - Filings
- 7 weeks ago - Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform - GlobeNewsWire
- 2 months ago - Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - GlobeNewsWire
- 2 months ago - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. - GlobeNewsWire
- 2 months ago - Nexalin Technology Registration statement - Filings
- 2 months ago - Nexalin Technology Quarterly report - Filings